View
215
Download
0
Tags:
Embed Size (px)
Citation preview
Lecture 3Antimicrobials and Susceptibility
tests
Dr. Abdelraouf A. Elmanama
Islamic University-Gaza
Medical Technology Department
Lecture outlines
• Kirby-Bauer susceptibility test
• Antimicrobial profiles selection
• Reporting susceptibility test
What Does the Laboratory Need to Knowabout Antimicrobial Susceptibility Testing (AST)?
• Which organisms to test?
• What methods to use?
• What antibiotics to test?
• How to report results?
What Does a Laboratory Need to Know about AST? (con’t)
• How to determine the clinical significance of results?
• How to ensure accuracy of results?
–Quality control / quality assurance
• When to call the MD, infection control, public health?
What Does a Laboratory Need to Know about AST? (con’t)
• When to ask for help?
• Where to go for help?
Routine Susceptibility Tests
• Disk diffusion (Kirby Bauer)
• Broth micro-dilution MIC
– NCCLS reference method
• Etest
Zone Interpretive Criteria (mm)
Drug
Disk content
(ug)ResIntSusc
Cefazolin30 1415-17 18
Gentamicin10 1213-14 15
Flash presentation for summary
• Qualitative results
– Susceptible
– Intermediate – may respond if infection is at body site where drug concentrates (e.g. urine) or if higher than normal dose can be safely given
– Resistant
Disk Diffusion Test
Clinical Conditions when MICs are Useful
• Endocarditis• Meningitis• Septicemia• Osteomyelitis• Immunosuppressed patients (HIV, cancer, etc.)• Prosthetic devices• Patients not responding despite “Sensitive results”
MIC
• Minimal inhibitory concentration• The lowest concentration of
antimicrobial agent that inhibits the growth of a bacterium
• Interpret:– Susceptible– Intermediate– Resistant
Inoculum Preparation MIC Testing
(NCCLS Reference Method)
• Standardize inoculum suspension
• Final inoculum concentration– 3 – 5 x 105 CFU/ml– (3 – 5 x 104 CFU/well)
Examining Examining purity platepurity plate
Reflected lightReflected light
Transmitted lightTransmitted light
Empirical Treatment
Infants 1-3 mosAmpicillin + cefotaxime or ceftriaxone
Immunocompetent children > 3 mos and adults <55Cefotaxime or ceftriaxone +
vancomycin
Adults > 55 and adults of any age with alcoholism or other debilitating illnesses
Ampicillin + cefotaxime or ceftriaxone + vancomycin
Hospital-acquired meningitis, posttraumatic or postneurosurgery meningitis, neutropenic patients, or patients with impaired cell-mediated immunity
Ampicillin + ceftazidime + vancomycin
• Ceftazidime should be substituted for ceftriaxone or cefotaxime in neurosurgical patients and in neutropenic patients
Specific treatment
• N. meningitidis
– Penicillin sensitive Penicillin G or Ampicillin
– Penicillin-resistant Ceftriaxone or cefotaxime
Chemoprophylaxis for N. meningitidis
• Rifampin 600 mg every 12 h for 2 days in adults and 10 mg/kg every 12 h for 2 days in children >1 year
• Or
• One dose of ciprofloxacin (750 mg)
• One dose of azithromycin (500 mg)
• One intramuscular dose of ceftriaxone (250 mg)
• Rifampicin is not recommended in pregnant women.
• Pneumococci
– Penicillin-sensitive Penicillin G
– Penicillin-intermediate Ceftriaxone or cefotaxime
– Penicillin-resistant (Ceftriaxone or cefotaxime) + vancomycin
• Gram-negative bacilli (except Pseudomonas spp.) Ceftriaxone or cefotaxime
• Pseudomonas aeruginosa Ceftazidime
• Staphylococci spp.– Methicillin-sensitive Nafcillin– Methicillin-resistant Vancomycin
• Listeria monocytogenes Ampicillin + gentamicin• Haemophilus influenzae Ceftriaxone or
cefotaxime• Streptococcus agalactiae Penicillin G or
ampicillin• Bacteroides fragilis Metronidazole• Fusobacterium spp. Metronidazole